U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unresectable Colorectal Adenocarcinoma

MedGen UID:
1747614
•Concept ID:
C5419194
•
Neoplastic Process

Definition

Colorectal adenocarcinoma that is not amenable to surgical resection. [from NCI]

Professional guidelines

PubMed

Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease.
Kibbi N, Owen JL, Worley B, Wang JX, Harikumar V, Downing MB, Aasi SZ, Aung PP, Barker CA, Bolotin D, Bordeaux JS, Cartee TV, Chandra S, Cho NL, Choi JN, Chung KY, Cliby WA, Dorigo O, Eisen DB, Fujisawa Y, Golda N, Halfdanarson TR, Iavazzo C, Jiang SIB, Kanitakis J, Khan A, Kim JYS, Kuzel TM, Lawrence N, Leitao MM Jr, MacLean AB, Maher IA, Mittal BB, Nehal KS, Ozog DM, Pettaway CA, Ross JS, Rossi AM, Servaes S, Solomon MJ, Thomas VD, Tolia M, Voelzke BB, Waldman A, Wong MK, Zhou Y, Arai N, Brackett A, Ibrahim SA, Kang BY, Poon E, Alam M
JAMA Oncol 2022 Apr 1;8(4):618-628. doi: 10.1001/jamaoncol.2021.7148. PMID: 35050310
Regional Therapies for Colorectal Liver Metastases: Systematic Review and Clinical Practice Guideline.
Karanicolas P, Beecroft JR, Cosby R, David E, Kalyvas M, Kennedy E, Sapisochin G, Wong R, Zbuk K; Gastrointestinal Disease Site Group
Clin Colorectal Cancer 2021 Mar;20(1):20-28. Epub 2020 Oct 12 doi: 10.1016/j.clcc.2020.09.008. PMID: 33257278
Radioembolization in the treatment of unresectable liver tumors: experience across a range of primary cancers.
Coldwell D, Sangro B, Salem R, Wasan H, Kennedy A
Am J Clin Oncol 2012 Apr;35(2):167-77. doi: 10.1097/COC.0b013e3181f47923. PMID: 21127414

Recent clinical studies

Etiology

Survival Benefit of Primary Tumor Resection Combined With Chemotherapy in Patients With Unresectable Colorectal Mucinous Adenocarcinoma With Liver Metastasis.
Liao SW, Zhan JQ, Liu CT, Yu HT, Wen MJ
Am J Clin Oncol 2024 Jan 1;47(1):30-39. Epub 2023 Oct 17 doi: 10.1097/COC.0000000000001055. PMID: 38148710Free PMC Article
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW
Lancet Oncol 2018 May;19(5):660-671. Epub 2018 Mar 16 doi: 10.1016/S1470-2045(18)30140-2. PMID: 29555258
Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Mochizuki S, Yoshino T, Kojima T, Fuse N, Ikematsu H, Minashi K, Yano T, Tahara M, Kaneko K, Doi T, Koike K, Ohtsu A
Jpn J Clin Oncol 2010 Oct;40(10):933-7. Epub 2010 May 21 doi: 10.1093/jjco/hyq058. PMID: 20494948
Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
Cartwright T, Kuefler P, Cohn A, Hyman W, Berger M, Richards D, Vukelja S, Nugent JE, Ruxer RL Jr, Boehm KA, Asmar L
Clin Colorectal Cancer 2008 Nov;7(6):390-7. doi: 10.3816/CCC.2008.n.052. PMID: 19036692
The impact of the introduction of irinotecan and oxaliplatin on the outcome of patients with advanced colorectal cancer.
Lelli G, Carandina I, Urbini B, Guarino S, Modonesi C, Pedriali M
J Chemother 2007 Oct;19(5):590-5. doi: 10.1179/joc.2007.19.5.590. PMID: 18073160

Diagnosis

Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Mochizuki S, Yoshino T, Kojima T, Fuse N, Ikematsu H, Minashi K, Yano T, Tahara M, Kaneko K, Doi T, Koike K, Ohtsu A
Jpn J Clin Oncol 2010 Oct;40(10):933-7. Epub 2010 May 21 doi: 10.1093/jjco/hyq058. PMID: 20494948
The impact of the introduction of irinotecan and oxaliplatin on the outcome of patients with advanced colorectal cancer.
Lelli G, Carandina I, Urbini B, Guarino S, Modonesi C, Pedriali M
J Chemother 2007 Oct;19(5):590-5. doi: 10.1179/joc.2007.19.5.590. PMID: 18073160

Therapy

Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW
Lancet Oncol 2018 May;19(5):660-671. Epub 2018 Mar 16 doi: 10.1016/S1470-2045(18)30140-2. PMID: 29555258
Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Mochizuki S, Yoshino T, Kojima T, Fuse N, Ikematsu H, Minashi K, Yano T, Tahara M, Kaneko K, Doi T, Koike K, Ohtsu A
Jpn J Clin Oncol 2010 Oct;40(10):933-7. Epub 2010 May 21 doi: 10.1093/jjco/hyq058. PMID: 20494948
Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
Cartwright T, Kuefler P, Cohn A, Hyman W, Berger M, Richards D, Vukelja S, Nugent JE, Ruxer RL Jr, Boehm KA, Asmar L
Clin Colorectal Cancer 2008 Nov;7(6):390-7. doi: 10.3816/CCC.2008.n.052. PMID: 19036692
The impact of the introduction of irinotecan and oxaliplatin on the outcome of patients with advanced colorectal cancer.
Lelli G, Carandina I, Urbini B, Guarino S, Modonesi C, Pedriali M
J Chemother 2007 Oct;19(5):590-5. doi: 10.1179/joc.2007.19.5.590. PMID: 18073160
Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
Kim TW, Kang WK, Chang HM, Park JO, Ryoo BY, Ahn JS, Zang DY, Lee KH, Kang YK, Kim SR, Kim HK; Korean Cancer Study Group
Acta Oncol 2005;44(3):230-5. doi: 10.1080/02841860510029590. PMID: 16076694

Prognosis

Survival Benefit of Primary Tumor Resection Combined With Chemotherapy in Patients With Unresectable Colorectal Mucinous Adenocarcinoma With Liver Metastasis.
Liao SW, Zhan JQ, Liu CT, Yu HT, Wen MJ
Am J Clin Oncol 2024 Jan 1;47(1):30-39. Epub 2023 Oct 17 doi: 10.1097/COC.0000000000001055. PMID: 38148710Free PMC Article
Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Mochizuki S, Yoshino T, Kojima T, Fuse N, Ikematsu H, Minashi K, Yano T, Tahara M, Kaneko K, Doi T, Koike K, Ohtsu A
Jpn J Clin Oncol 2010 Oct;40(10):933-7. Epub 2010 May 21 doi: 10.1093/jjco/hyq058. PMID: 20494948
The impact of the introduction of irinotecan and oxaliplatin on the outcome of patients with advanced colorectal cancer.
Lelli G, Carandina I, Urbini B, Guarino S, Modonesi C, Pedriali M
J Chemother 2007 Oct;19(5):590-5. doi: 10.1179/joc.2007.19.5.590. PMID: 18073160
Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
Kim TW, Kang WK, Chang HM, Park JO, Ryoo BY, Ahn JS, Zang DY, Lee KH, Kang YK, Kim SR, Kim HK; Korean Cancer Study Group
Acta Oncol 2005;44(3):230-5. doi: 10.1080/02841860510029590. PMID: 16076694

Clinical prediction guides

Survival Benefit of Primary Tumor Resection Combined With Chemotherapy in Patients With Unresectable Colorectal Mucinous Adenocarcinoma With Liver Metastasis.
Liao SW, Zhan JQ, Liu CT, Yu HT, Wen MJ
Am J Clin Oncol 2024 Jan 1;47(1):30-39. Epub 2023 Oct 17 doi: 10.1097/COC.0000000000001055. PMID: 38148710Free PMC Article
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW
Lancet Oncol 2018 May;19(5):660-671. Epub 2018 Mar 16 doi: 10.1016/S1470-2045(18)30140-2. PMID: 29555258
Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Mochizuki S, Yoshino T, Kojima T, Fuse N, Ikematsu H, Minashi K, Yano T, Tahara M, Kaneko K, Doi T, Koike K, Ohtsu A
Jpn J Clin Oncol 2010 Oct;40(10):933-7. Epub 2010 May 21 doi: 10.1093/jjco/hyq058. PMID: 20494948

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...